ReviewPharmaceuticals (Basel, Switzerland)2026
Deconstructing the Master Switch: Advances in Direct NLRP3 Inhibition.
Review in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
As a bona fide "master switch," NOD-like receptor family pyrin domain containing 3 (NLRP3) functions not only as an inflammatory mediator but also as a primary sensor of metabolic stress and danger signals. Its dysregulation has been implicated in an exceptionally broad spectrum of human diseases, making it one of the most intensively studied therapeutic targets. While the discovery of the first direct antagonist MCC950 marked a turning point, the subsequent explosion of diverse inhibitor classes demands a systematic, up-to-date evaluation. This review comprehensively analyzes the current landscape of direct NLRP3 inhibitors, focusing on how recent structural breakthroughs illuminate specific mechanism-of-action differences. We systematically reviewed peer-reviewed literature from 2015 to 2026, categorizing small-molecule inhibitors based on their chemical scaffolds and binding pockets as revealed by cryo-EM and X-ray crystallography data. By mapping these structural insights into functional outcomes, we provide a definitive molecular-level analysis designed to guide the rational design and optimization of next-generation NLRP3-targeted therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.